NCT05584787

Transperineal Laser Ablation for Low- and Intermediate Risk Prostate Cancer: a Single Cohort Analysis

Transperineal Laser Ablation for Low and Intermediate Risk Prostate Cancer: a Single Cohort Analysis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: San Carlo di Nancy Hospital · Academic / Other
• Sex: Male
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective study is to test the efficacy of Echolaser transperineal focal therapy in patients with low- and intermediate risk prostate cancer. The main question it aims to answer are: 1. short and intermediate term oncological outcomes after laser focal therapy, 2. functional outcomes and quality of life after treatment. Participants affected by low risk prostate cancer will undergo trans perineal laser focal therapy. Multiparametric prostate MRI will be perform after 3 and 12 months for oncological control. Re-fusion biopsy will be perform after 12 months. Functional outcomes and quality of life will be assess at 3, 6 and 12 months.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
PROCEDURE	Soractelite Echolaser Transperineal focal laser ablation	US/MRI fusion laser ablation of low- and intermediate risk prostate cancer

Timeline

• Start date: 2021-05-01
• Primary completion: 2024-02-29
• Completion: 2024-03-30
• First posted: 2022-10-18
• Last updated: 2024-01-10

Locations

1 site across 1 country: Italy